RxDoctor Payments DataLook up a doctor →

Kelley Jacobs

Primary Care · Dillon, SCNPI 1952721672

Payments from drug & device makers

$5,718in general payments, 2019–2025

Across 344 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novartis$340
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$262
  • GSK$257
  • Pfizer$233
  • Johnson & Johnson$224
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$5,718100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,718 in reported general payments places this provider in the 90th percentile of 115 primary care providers in South Carolina.

See all primary care providers in South Carolina

Medicare billing

Part B allowed, 2024
$22,913
Medicare patients
183
Services billed
736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin54$50,339
TrulicityDulaglutide15$13,878
EliquisApixaban11$12,901
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$10,087
Sucralfate13$2,768
Novolin 70-30Insulin Nph Hum/Reg Insulin Hm13$1,873
Rosuvastatin Calcium88$1,092
Colchicine14$913
Atorvastatin Calcium54$794
Losartan Potassium63$577
Gabapentin46$505
Omeprazole37$478
Fluticasone Propionate24$447
Metoprolol Succinate28$442
Diclofenac Sodium20$332

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$173$50,33954 claims
Lilly USA, LLCTrulicity$117$13,87815 claims
PfizerEliquis$233$12,90111 claims
GSKTrelegy Ellipta$257$10,08714 claims
Scilex Pharmaceuticals Inc.Colchicine$25$91314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 115 primary care providers in South Carolina.

Other primary care in Dillon

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →